Stretching a doublet into a triplet for FLT3 AML
Keith W. Pratz · 2026
Read Stretching a doublet into a triplet for FLT3 AML by Keith W. Pratz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13543938.txt.
Description
Some leukemias wired with FLT3 mutations resist standard gentle therapy, and Keith Pratz comments on a study that adds a third drug to the fight. The standard doublet pairs azacitidine with venetoclax. The commented trial adds gilteritinib, a targeted FLT3 blocker, making a triplet. Response rates reported in the underlying study were remarkably high for this hard subtype.
Pratz urges both excitement and patience. The triplet suppresses bone marrow more heavily, a serious cost for frail patients. A randomized trial now enrolling will test the triplet against the doublet directly. Until it reports, routine use should wait. The commentary captures a familiar oncology moment: a promising combination, a plausible price, and a verdict that only randomization can deliver.
Catalog record
| CREATOR | Keith W. Pratz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |